1-20 of 2159 < first | prev | | last >
  • The Changing Biopharma Risk Equation

    Multinational survey of pharma execs offers insight on pharmaceutical companies’ growth strategies and risk management in the challenging biologics landscape

    Andrew Bulpin, vice president, Process Solutions, Merck KGaA
  • GMP in Cleanroom Maintenance: Myths and Facts

    Every cleanroom requires a carefully controlled environment maintained with Good Manufacturing Practices to prevent contamination

    Omar Lopez, MBA, Pristine Environments Inc.
  • 4 Steps for Managing Biopharmaceutical Projects

    In order for biopharma companies to move quickly and adaptively enough, an outstanding project management process is critical

    Tracy TreDenick, Head of Regulatory and Quality, and Senior Consultant, and Julie Spyrison Associate Director, Regulatory Operations at BioTechLogic, Inc.
  • No-Compromise APIs

    Hyderabad-based API provider Neuland Labs sheds the stigma of Indian manufacturers by building stringent quality control into every process

    Karen Langhauser, Chief Content Director
  • Financial Justification in Pharma

    Selection of any pharma manufacturing process, including supply chain and quality assurance practices, requires financial justification

    Girish Malhotra, PE, President, EPCOT International
  • Three Big Risks in 3D Printing Pharmaceuticals

    Are the risks of leveraging this new technology outweighing the benefits for drug makers?

    Timothy Gosnear, Senior Vice President in Major Accounts, and Daniel Brettler, Life Science and Technology Practice Leader for Conner Strong & Buckelew
  • Why Zombies Would Be Unstoppable if They Used a QMS

    Though a zombie apocalypse is decidedly scary and unpleasant, zombies tend to lack the qualities and traits that truly cataclysmic destruction requires. A QMS could help zombies take their apocalypse to the next level.

    Marci Crane Localization Manager, MasterControl
  • Pound and Penny Wise

    With capital spending on the rise, readers prioritize innovation geared toward increasing speed and efficiency

    Karen Langhauser, Chief Content Director
  • Planting the Seed for Speed

    iBio’s commercial-scale biotherapeutics manufacturing facility built speed and flexibility into every step – from initial design and construction to daily operations

    Karen Langhauser, Chief Content Director
  • Staying Ahead of New Statutes

    Impending serialization regulations are driving trends in pharma

    Sean M. Riley, Editorial Director, PMMI
  • Tech Takes a Back Seat

    Defining innovation with technology slows, as results-driven solutions take the industrial wheel

    Karen Langhauser, Chief Content Director
  • Holding the Diagnostic Mirror

    Only those pharma companies with enough courage and imagination to learn and apply lessons from other industry leaders can hope to break from the pack

    Thibaut Dedeurwaerder and Jonathan Tilley, McKinsey & Company
1-20 of 2159 < first | prev | | last >